ACP
DNLI icon

Altitude Crest Partners’s Denali Therapeutics DNLI Stock Holding History

Altitude Crest Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-209,613
Closed -$4.3M – 11
2024
Q1 		$4.3M Buy
+209,613
New +$3.94M 1.84% 19

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Altitude Crest Partners's DNLI Position: Q2 2024 in Review

Altitude Crest Partners sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 209,613 shares — an estimated $4.3M sold.

Altitude Crest Partners first reported a position in DNLI in Q1 2024 and held it in 1 quarter. The position peaked at $4.3M in Q1 2024. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • Altitude Crest Partners reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 209,613 Denali Therapeutics shares in Q2 2024, an estimated $4.3M.
  • Altitude Crest Partners first reported a position in Denali Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Denali Therapeutics position peaked at $4.3M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.